Vaccine Design and Testing – News and Features

After delays, the FDA has greenlit the Novavax COVID vaccine for targeted groups. Learn more about the approval and what it means for non-mRNA COVID-19 vaccine access.

A study from NTNU reveals that JAK inhibitors, prescribed for autoimmune diseases like rheumatoid arthritis, may suppress the body’s antiviral defenses, making patients more vulnerable to viruses like influenza and SARS-CoV-2.

A research team set out to trigger a broadly neutralizing response by developing a vaccine that uses specifically engineered immunogens, in what is known as a germline-targeting strategy. Human trial results highlight the promise of the strategy.

A study combining data from two separate Phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in one trial, further advance them.

To make it easier for children to receive all of their vaccines, MIT researchers are working to develop microparticles that can release their payload weeks or months after being injected.

Annual flu shots could become a thing of the past under a new vaccine strategy. Researchers have described a vaccine that protects against H1N1 swine flu and can also protect against influenza in humans and birds.

Researchers have employed a cross-species immunological analysis to provide new insights into a smallpox vaccine's immunogenicity and safety against the monkeypox virus.

An AI model called EVE-Vax uses evolutionary, biological and structural information about a virus to predict and design surface proteins likely to occur as the pathogen mutates.

Scientists have used computer modeling to illustrate how a specific class of antibodies use lipids to recognize the HIV virus. Their work highlights antibody features that could help people design better vaccines.

This article explores how synthetic biology is revolutionizing therapeutics through engineered cells, precision genetic circuits and AI-driven design, with applications in cancer treatment, vaccine development and next-generation immunotherapies.